Analgesia an sedation in acute pancreatitis;Analgesia y sedación en la pancreatitis aguda

Medicina Intensiva

Volumn 27, Issue 2, 2003, Pages 118-130

  Gil Cebriana J ^a,b   Bello Camara M P ^a   Rodriguez Yaneza J C ^a   Fernandez Ruiz, Y A ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^b NONE   (Spain)

Author keywords

Acute pancreatitis; Analgesia; Epidural; Opioids; Patient controlled analgesia; Sedation

Indexed keywords

BUPRENORPHINE; CLOMETHIAZOLE; FENTANYL DERIVATIVE; LORAZEPAM; MIDAZOLAM; MORPHINE; OPIATE; PETHIDINE; PROPOFOL; SUFENTANIL; TRAMADOL;

ACUTE PANCREATITIS; ANALGESIA; CELIAC GANGLION; DRUG MECHANISM; EPIDURAL ANESTHESIA; HEPATOBILIARY SYSTEM; HUMAN; NERVE BLOCK; NOCICEPTION; PAIN; PATIENT CONTROLLED ANALGESIA; REVIEW; SEDATION;

EID: 0037297847     PISSN: 02105691     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-5691(03)79879-9     Document Type: Review

References (82)

1. Practice parameters for systemic intravenous analgesia and sedation for adult patients in the intensive care unit. Society of Critical Care Medicine's Vision for Critical Care 1995:5.
2. Encuesta sobre sedación y analgesia en las Unidades de Medicina Intensiva de la Comunidad Andaluza. Grupo de Trabajo de Sedación y Analgesia de la SAMIUC. Comunicada en el XX Congreso de la SAMIUC; 1998; Marbella.
3. Irving GA. Pancreatitis aguda. En: Wallace MS, Dunn JS, Yaksh TL, editores. Clínicas anestesiológicas. Dolor: Mecanismos nociceptivos y neuropáticos con correlaciones clínicas. México; McGraw-Hill Interamericana, 1977.
4. González Machado JL. Transmisión nociceptiva. En: Fisiología aplicada a la anestesia. Madrid: Ediciones Ergon, S.A. Fundación Europea para la Enseñanza de la Anestesiología en formación continuada. Cap 18: 1997; p. 347-63.
5. McMahon S, Koltzenburg M. The changing role of primary aferent neurons in pain. Pain 1990;43:269-72.
6. Rexed B. A cytoarchitectonic atlas of spinal cord in the cat. J Comparat Neurol 1954;297-380.
7. Sorkin LS. Farmacología y fisiología básicas del dolor agudo. Clin Anest N A (ed. esp.) 1997;2:245-59.
8. Flórez J, Reig E. Terapéutica farmacológica del dolor. Cap 1. Pamplona: Eunsa, 1993; p. 19-39.
9. Klepstad P, Maurset A, Moberg ER, Oye I. Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 1990;187:513-8.
10. Puig Riera de Conías MM. Bases fisiológicas de los analgésicos no convencionales. En: Carlos R, Baños JE. editores. Monografías Dr. Antonio Esteve. Barcelona: Doyma, 1994.
11. Feria Rodríguez M. Analgésicos antipiréticos y antiinflamatorios no esteroideos. Medicine (Madrid) 1998; 108:4891-907.
12. Flórez J, Reig E. Terapéutica farmacolígica del dolor. Cap 2. Pamplona: Eunsa, 1993; p. 41-80.
13. Flórez Beledo J. Fármacos analgésicos opioides. Medicine (Madrid) 1998;108:4908-19.
14. Dayer P, Desmeules J, Collart L. Pharmacologie du tramadol. Drugs 1997; 53(Suppl 2):18-24.
15. Radnay PA, Duncalf D, Novakovic M, Lesser ML. Common bile duct pressure changes after fentanyl, morphine, meperidine. butorphanol and naloxone. Anesth Analg 1984;63:441-4.
16. Jones R, Detmer M. Hill AB, Bjoraker DC, Pandit U. Incidence of choledocoduodenal sphincter spasm during fentanylsupplemented anesthesia. Anesth Analg 1981;60:638-40.
17. Butsch JL, Okoli JA. The effect of nalbuphine on the common bile duct pressure. Am Surg 1988;54:253-5.
18. Lauritz J. Biliary colic following morphine. Anaesth Intensive Care 1979;4:384.
19. Mills GH, Goddard JM. A case of patient-controlled analgesia exacerbating postoperative pain. Anaesthesia 1991;46:893.
20. Wapshaw H. The pancreatic side-effects of morphine. BMJ 1953;1:373-5.
21. Skaife P, Kingsnorth AN. Acute pancreatitis: assessment and management. Posgrad Med 1996;72:277-83.
22. Hynynen MJ. Turunen M, Korttila KT. Effects of alfentanil and fentanyl on common biled duct pressure. Anesth Analg 1986;65:370-2.
23. Vatashsky F. Haskel Y, Beilin B, Aronson HB. Common bile duct pressure in dogs after opiate injection - epidural versus intravenous route. Can Anaesth Soc J 1984;31:650-3.
24. Isenhower HL, Mueller BA. Selection of narcotic analgesics for pain associated with pancreatitis. Am J Health Syst Pharm 1998;55:480-6.
25. Vatashsky F, Haskel Y. The effect of nalbuphine (Nubain) compared to morphine and phentanyl on common bile duct pressure. Curr Ther Res 1985;37:95-102.
26. Radnay PA, Brodman E, Mankikar D, Duncalf D. The effect of equianalgesic doses of fentanyl, morphine, meperidine and pentazocine on common bile duct pressure. Anaesthetist 1980;29:26-9.
27. Thune A, Baker RA, Saccone GT, Owen H, Toouli J. Differing effects of pethidine and morphine on human sphincter of Oddi motility. Br J Surg 1990;77:992-5.
28. McCammon RL, Stoelting RK, Madura JA. Effects of butorphanol, nalbuphine and fentanyl on intrabiliry tract dynamics. Anesth Analg 1984;63:139-42.
29. Economou G, Ward-McQuald JN. A cross-over comparison of the effect of morphine, pethidine, pentazocine, and phenazocine on biliary pressure. Gut 1971;12:218-21.
30. Tigerstedt I, Turunen M, Tammisto T, Hastbacka J. The effect of buprenorphine and oxydocone on the intracholedocal passage pressure. Acta Anaesth Scand 1981;25:99-102.
31. Greenstein AJ, Kaynan A, Singer A, Dreiling DA. A comparative study of pentazocine and meperidine on the biliary passage pressure. Am J Gastroenterol 1972;58:417-27.
32. Vatashsky E, Haskel Y. Effect of nalbuphine on intrabiliary pressure in the early postoperative period. Can Anaesth Soc J 1986;33:433-6.
33. Helm JF, Venu RP, Geenen JE, Hogan WJ, Dodds WJ, Toouli J, et al. Effects of morphine on the human sphincter of Oddi. Gut 1988;89:1402-7.
34. Elta GH, Barnett JL. Meperidine need not be proscribed during sphinmcter of Oddi manometry. Gastrointest Endosc 1994; 40:7-9.
35. Staritz M, Poralla T, Manns M, Meyer Zum Buschenfelde KH. Effect of modem analgesic drugs (tramadol, pentazocine and buprenorphine) on the bile duct sphincter in man. Gut 1986;27: 567-9.
36. Cuer JC, Dapoigny M, Ajmi S, Larpent JL, Lunaud B, Ferrier C, et al. Effects of buprenorphine on motor activity of the sphincter of Oddi in man. Eur J Clin Pharmacol 1989;36:203-4.
37. Vieira ZE, Zsigmonf EK, Duarate B, Renigers SA, Hirota K. Evaluation of fentanyl and sufentanil on the diameter of the common bile duct by ultrasonography in man: a double blind, placebo controlled study. Int J Clin Pharmacol Ther 1994;32:274-7.
38. Sechzer PH. Studies in pain with the analgesic demand system. Anesth Analg 1971;50:1-10.
39. Marshall H, Porteous C, McMillan I, McPherson SG, Nimmo WS. Relief of pain by infusion of morphine after operation: does tolerance develop? BMJ 1985;291:1921-8.
40. a ed. Cap 14. Mexico: McGraw-Hill Interamericana, 1996; p. 327-51.
41. Sluka KA. Blockade of N- and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. J Pharmacol Exp Ther 1998;287:232-7.
42. Nadasdi L, Yamashiro D, Chung D, Tarczy-Hornoch K, Adriaenssens P, Ramachandran J. Structure-activity analysis of a conus peptide blocker of N-type neuronal calcium channels. Biochemistry 1995;34:8076-81.
43. Malmberg AB, Yaksh TL. Effec of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 1995;60:83-90.
44. Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 1994;269:1117-23.
45. Brose WG, Gutlove DP, Luther RR, Bowersox SS, McGuire D. Use of intrathecal SNX-II1, a novel, N-type, voltage sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain 1997;13:256-9.
46. McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol 1997;30:400-3.
47. Bowersox S, Mandema J, Tarczy-Hornoch K, Miljanich G, Luther RR. Pharmacokinetics of SNX- II1, a selective N-type calcium channel blocker, in rats and cynomolgus monkeys. Drug Metad Dispos 1997;25:379-83.
48. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, et al. Broad-spectrum, nonopioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998;279:77-81.
49. Khan IM, Yaksh TL, Taylor P. Epibatidine binding sites and activity in the spinal cord. Brain Res 1997;753:269-82.
50. Badio B, Daly JW. Epibatidine, a potent analgesic and nicotinic agonist. Mol Pharmacol 1994;45:563-9.
51. Okabe K, Natsume M. Total synthesis of a frog poison, (+/-)-epibatidine, a potent non-opioid analgesic. Chem Pharm Bull 1994;42:1432-6.
52. Damaj MI, Fei-Yin M, Dukat M, Glassco W, Glennon RA, Martin BR. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther 1998;284:1058-65.
53. Daly JW. Thirty years of discovering arthropod alkaloids in amphibian skin. J Natl Prod 1998;61:162-72.
54. Badio B, Garraffo HM, Plummer CV, Padgett WL, Daly JW. Synthesis and nicotinic activity of epiboxidine: an isoxazole analogue of epibatidine. Eur J Pharmacol 1997;32:189-94.
55. Carregui R, Abizanda R, Ferrándiz A, Mut T. Analgesia regional. En: Castañeda FS, coordinador. Sedación y analgesia en el paciente grave. Cap. 2. Barcelona: Edikamed, 1994;p. 21-38.
56. Bromage PR. Analgesia epidural. Barcelona: Salvat Editores S.A., 1984.
57. Gil-Cebrián J, Bello-Cámara MP, Saldaña-González FJ, Huertos-Ranchal MJ. Analgesia epidural. En: Barranco Ruiz F, Blasco Morilla J, Mérida Morales A, Muñoz Sanchez MA, Jareño Chaumel A, Cózar Carrasco J, et al, editores. Salobreña: Ed. Alhulia. SAMIUC, 1999; p. 1443-59.
58. Kvalheim L, Reiestad F. Intrapleural catheter in the management of postoperative pain. Anesthesiology 1984;61:A231.
59. Reiestad F, Stromkag KE, Heen L. Intrapleural catheter for analgesia after thoracotomy in adult patients. Acta Anaesthesiol Scand 1987;31:237.
60. Aliaga L, Dfaz Meco JL. Analgesia postoperatoria con anestésicos locales. En: Miranda A, editor. Dolor postoperatorio. Estudio, valoración y tratamiento. Barcelona: Editorial JIMS, 1992.
61. Sánchez Rivero D, Saldaña González FJ, Gil Cebrián J, Bello Cámara MP. Sedación y analgesia. En: Barranco Ruiz F, Blasco et al, editores. Principios de urgencias, emergencias y cuidados críticos. Salobreña: Alhulia-SAMIUC, 1999; p. 1405-41.
62. Scott PV. Interpleural regional analgesia: detection of the interpleural space by saline infusion. Br J Anaesth 1991;66: 131-3.
63. François T, Pillet F, Blanloeil Y. Anesthesie interpleurale. Cah Anesthesiol 1992;40:469-73.
64. Rykowski JJ, Hilgier M. Continuous celiac plexus block in acute pancreatitis. Reg Anesth 1995;20:528-32.
65. a ed. México: McGraw-Hill Interamericana, 1996; 348-9.
66. Aitkenhead AR, Pepperman ML, Willats SM, Coates PD, Park GR, Bodenham AR, et al. Comparison of propofol and midazolam for sedation in critically ill patients. Lancet 1989;2:704-9.
67. Navapurkar VU, Menon DK, Jones JG. Propofol protects rat hepatocytes against an oxidant stress. Br J Anaesth 1996;77: P691.
68. Kahraman S, Kilinç DD, Erdem K. Propofol attenuates formation of lipid peroxides in tourniquet-induced ischaemia-reperfusion injury. Br J Anaesth 1997;78:279-81.
69. Cockshott ID. The pharmacokinetics of propofol in the ICU patient. J Drug Dev 1991;4(Suppl 3):29-36.
70. Valente JF, Anderson GL, Branson RD, Johnson DJ, Davis K Jr, Porembka DT. Disadvantages of prolonged propofol sedation in the critical care unit. Crit Care Med 1994;22:710-2.
71. Malacrida R, Fritz ME, Suter PM, Crevoisier C. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med 1991;20:1123-6.
72. Vree TB, Shimoda M, Driessen JJ, Guelen PJ, Janssen TJ, Termond EF, et al. Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients. Clin Pharmacol Ther 1989;46:537-44.
73. Driessen JJ, Vree TB, Guelen PJ. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long term infusion in ICU patients. Acta Anaesthesiol Belg 1991;42:149-55.
74. Patel IH, Soni PP, Fukuda EK, Smith DF, Leier CV, Boudolas H. The pharmacokinetics of midazolam in patients with congestive heart failure. Br J Clin Pharmacol 1990;29:565-9.
75. Shelly MP, Sultan MA, Bodenham A, Park GR. Midazolam infusions in critically ill patients. Eur J Anaesthesiol 1991; 8:21-7.
76. Pohlman AS, Simpson KP, Hall JB. Continuous intravenous infusion of Iorazepam and midazolam in the treatment of acute agitation syndromes during mechanical ventilatory support. Crit Care Med 1994;22:1241-7.
77. a ed. México: McGraw-Hill Interamericana. 1996; p. 408.
78. Chamorro C, De Latorre FJ, Montero A, Sánchez Izquierdo JA, Jareño A, Moreno JA, et al. Comparative study of propofol versus midazolam in the sedation of critically ill patients: results of a prospective, randomized, multicenter trial. Crit Care Med 1996;24:932-9.
79. Barrientos Vega R, Mar Sánchez-Soria M, Morales García C, Robas Gómez A, Cuena Boy R, Ayensa Rincón A. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med 1997;25:33-40.
80. Weinbroum AA, Halpern P, Rudick V, Sorkine P, Freeman M, Geller E. Midazolam versus propofol for long-term sedation in the ICU: a randomized prospective comparison. Intensive Care Med 1997;23:1258-63.
81. Carrasco G, Molina R, Costa J, Soler JM, Cabré L. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. Chest 1993;103: 557-64.
82. Boyd O, Mackay CJ, Rushmer F, Bennett ED, Grounds RM. Propofol or midazolam for short-term alterations in sedation. Can J Anaesth 1993;40:1142-7.